With the first strain of the coronavirus known more than years ago today, the virus is still present.
This is what you want to know about COVID-19 in 2025.
The Covid-19 pandemic began more than five years ago, however, the virus continues to circulate among global populations.
COVVI-19 is throughout the country, with 20 plus the district of Columbia that reports “very high” grades of Sras-Cov-2 between December 29 and January 4, according to the new knowledge of the centers for the centers for the centers for the centers for Disease control and Americans and prevention (CDC). The information shows that 6. 9% of all COVVI-19 tests throughout the country became positive the week ending on January 4.
Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, sore throat, loss of taste or smell, fatigue and body aches, headache, nausea or vomiting or diarrhea, according to the CDC.
Experts told Very Well Health that there are “no distinct symptoms” that make the current most dominant variant different from others.
XEC is a subvariant of the Sars-COV-2. Il. Il-2-year-old cin The outbreak in the Scripps. info Study database.
“One of the reasons for fear is that XEC has moved temporarily to pass beyond the expansion of all other SARS-COV-2 variants in some spaces in Europe,” said Dr. Scott Roberts, a specialist in infectious diseases to Through Yale’s medicine, in a launch press. “The point of Xec infections they see in some countries have a higher temporarily compared to the varying variants in those same places. “
On September 30, the strain accounted for 10% of all Covid-19 cases. Between December 8 and December 21, the CDC knows that XEC accounts for 45% of all cases.
“At this point, the XEC variant turns out to be the maximum probably to obtain the legs below,” Dr. Eric Topol, founder of the Scripps Research Translation Institute, published in X, previously known as Twitter, said in September.
The vaccines are expected to be opposite paints to XEC and other Covid-19 variants.
The CDC estimates based on data that from October 1 through December 7 there have been between 2.5 to 4.4 million COVID-19 illnesses. Between 72,000 to 120,000 of those have resulted in hospitalization, and 8,200 to 13,000 have led to death.
“This shows that Covid-19 reasons for a giant number of severe illnesses, even when the overall degrees of Covid-19 activity are low compared to past periods,” the CDC said.
In May, the CDC published new directives on isolation. The replacement advised that other people who review positive for COVID-19 no longer want to stay out for five days; On the other hand, other people who have COVID-19 remain in the house until they have been without fever without medicine for at least 24 hours and their symptoms have improved for 24 hours.
The common aspect of Paxlovid comes with loss of appetite, yellowish skin and the white component of the eyes, pale stools, itching and abdominal pain.
The Food and Medicines Administration (FDA) approved Paxlovid in 2023 after the emergency use authorization was granted in December 2021.
The antiviral treatment drug has been developed through Pfizer and has an 89% relief in hospitalization and death in unvaccinated people.
Paxlovid will be taken within five days of the progression of symptoms.
Monica is a Newsweek journalist founded in Boston. Its purpose is to inform about the safeguarding of news. Monica joined Newsweek in 2024. Se graduated from Clark University, with a master’s degree from Clark University and Northwestern University. She named the Goldsmith Prize for Research finalist, as well as the George Polk Award winner for his paintings through the search for Phillips respirators with their breathing machines. You can tap on Monica by emailing m. sager@newsweek. com. Languages: English.